Prostate Cancer Articles | Page 3

Expert Shares Insight on Role of RT, Surgery in Prostate Cancer
Jonathan Warner, MD, discusses the evolving role of surgery and radiation therapy in the treatment landscape for patients with prostate cancer.
LDH a Predictor for OS in mCRPC Following Radium-223
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy
Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.
 
PARP Inhibitor Tested in mCRPC
Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.
Przemyslaw W. Twardowski, MD, discusses a variety of factors to consider when treating patients with prostate cancer.
Expert Discusses Degarelix and Other Developments in Prostate Cancer
Guru P. Sonpavde, MD, discusses degarelix, androgen-deprivation therapy, and ongoing trials with immunotherapy that are crucial to advancing the treatment of patients with prostate cancer.
Pal Shares Insight on Abundance of Options in GU Malignancies
Sumanta K. Pal, MD, discusses advancements in prostate cancer, bladder cancer, and promising results in kidney cancer.
Acquired Mutations Alter Epigenetic Identity in Prostate Cancer
Mathieu Lupien, MD, discusses this analysis of the influence of mutations on the epigenetics of prostate cancer.
Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer
Charles Drake, MD, PhD, discusses the current status of both PARP inhibitors and immunotherapy in prostate cancer, emphasizing that immunotherapy is still very much a player in the prostate cancer field, with ongoing trials exploring checkpoint inhibitors.
Expert Sheds Light on Prostate Cancer Screening Trial
E. David Crawford, MD, discusses the controversy surrounding the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, as well as the role of prostate-specific antigen testing for men with prostate cancer.
Publication Bottom Border
Border Publication
x